Dynavax (DVAX) Misses Q1 EPS by 2c

Dynavax (NASDAQ: DVAX) reported Q1 EPS of $0.22, $0.02 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $114 million versus the consensus estimate of $154.3 million.

GUIDANCE:

Dynavax anticipates 2022 revenues, operating expenses, and other costs to be in the ranges shown below, unchanged from the Company\'s previous financial guidance provided on February 28, 2022:

Full-year CpG 1018 adjuvant net product revenues of at least $550 million, with an associated gross margin of approximately 50%
Research and development expenses to be between approximately $55 - $70 million
Selling, general and administrative expenses to be between approximately $120 - $140 million
Interest expense of approximately $7 million

For earnings history and earnings-related data on Dynavax (DVAX) click here.

You May Also Be Interested In

• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• Goldman "broadly" raises estimates for LTL and truckload stocks
• BofA lists top 5 themes driving next $1tn in incremental semi sales